Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 429-270-1 | CAS number: 136210-30-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates ā in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: oral
- Remarks:
- other: two-generation study
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP guideline study with deviations: This study was originally planned as a one-generation study and later enhanced to a two-generation study. As deviation to the guidelines of a two-generation study histopathology of F1 parental rats was done only in liver and kidneys.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 416 (Two-Generation Reproduction Toxicity Study) (2001)
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Duration of treatment / exposure:
- Total duration of in-Life Phase: 281 days (day 1 = first day of administration). The test substance or vehicle was administered to the animals from the first day of the study (F0) or from Day 29 after birth (F1) until spontaneous death, moribund sacrifice or until scheduled necropsy.
F0 animals were pretreated with the test substance for about 10 weeks, then the mating period of 3 weeks followed. After a gestation period of about 22 days litters were born and the dams were allowed to rear them. F0 females were killed and necropsied when about 28 days old F1 pups had been weaned. The weaned F1 offspring was treated further with the substance for at least 10 weeks premating period. The procedures during the mating, gestation and lactation period of F1 rats were the same as described for F0 rats. - Frequency of treatment:
- once daily
- Remarks:
- Doses / Concentrations:
40, 200 and 1000 mg/kg bw/day
Basis:
actual ingested - No. of animals per sex per dose:
- 25
- Control animals:
- yes, concurrent vehicle
- Dose descriptor:
- NOAEL
- Remarks:
- general toxicity
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Dose descriptor:
- LOAEL
- Remarks:
- general toxicity
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: Mild kidney effects (basophilic tubules, focal tubular dilation/hyaline casts) in F0 male rats combined with elevated absolute and/or relative kidney weights in F0 males and females and F1 rats
- Critical effects observed:
- not specified
Reference
In males of F0-generation basophilic tubules were slightly increased by severity at 1000 mg/kg and minimal focal tubular dilation/casts were slightly more frequent at 1000 mg/kg.
|
0 mg/kg |
40 mg/kg |
200 mg/kg* |
1000 mg/kg |
|
Male animals without kidney findings |
3 |
- |
1 |
- |
|
Male animals with Basophilic Tubules |
Grade 1 |
18 |
18 |
18 |
6 |
Grade 2 |
4 |
6 |
5 |
16 |
|
Grade 3 |
- |
- |
- |
2 |
|
Grade 4 |
- |
1 |
- |
- |
|
Male animals with Foc. Tub. Dil./Casts |
Grade 1 |
8 |
7 |
10 |
13 |
Grade 2 |
1 |
- |
- |
3 |
*in total kidneys of 24 animals examined
Although basophilic tubules and focal tubular dilation/hyaline casts are common spontaneous findings in male rats of this age these findings were concluded to be adverse, since they correlated with statistically significantly elevated absolute and/or relative kidney weights, evident for F0 and F1 rats at 1000 mg/kg. For F0 females slightly more frequent slight non-adverse tubular change of inner renal cortex were found at 1000 mg/kg and for F1 rats kidney histopathology was inconspicuous.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- A short term oral toxicity study (28-days; Bomhard, Bayer AG, 1992b) with the read across substance revealed no toxicological effects. The derived NOAEL was 1000 mg/kg bw/day. In a two-generation reproductive toxicity study mild kidney effects (basophilic tubules and focal tubular dilation/hyaline casts) were seen in males only at a dose of 1000 mg/kg bw/day. The basophilic tubules and focal tubular dilation/hyaline casts are common spontaneous findings in male rats of this age but as a worst case assumption these findings were concluded to be adverse, since they correlated with statistically significantly elevated absolute and/or relative kidney weights, evident for F0 and F1 rats at 1000 mg/kg. Thus, 1000 mg/kg turned out to be a LOAEL and 200 mg/kg a NOAEL in the study based on such kidney responses. It is not expected that a 90-days repeated dose toxicity study according to OECD TG 408 would substantially change the assessment of the substance, therefore the available information on repeated dose toxicity meets the tonnage driven data requirement of REACH.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
An oral subacute dose study (OECD TG 407; Bomhard, Bayer AG, 1992b) with the structural analogue aspartic acid, N,N'-[methylenebis(2-methyl-4,1-cyclohexanediyl)]bis-,1,1',4,4'-tetraethyl ester was conducted on 5 male and 5 female rats at doses of 0 (vehicle control), 40, 200 and 1000 mg/kg bw per day. Additional 10 animals (5 per sex) were used for further observation in a 2 -weeks post exposure period following treatment with 0 and 1000 mg/kg bw/day.
No mortality, no clinical signs and no effects on food-/water-consumption or body weight gain were observed. Hematology and histopathology revealed no conclusive signs of toxicologic relevance on blood and hematopoetic organs.
Neither clinical chemistry nor gross/histopathology revealed signs indicating substance-related metabolic or organ impairment.
Thus, the NOAEL was determined to be 1000 mg/kg bw/day.
Also available is a two-generation reproductive study (OECD 416) with the structural analogue. In this study groups of 25 male and 25 female F0 and F1 rats received once daily doses of 0, 40, 200 and 1000 mg/kg via gavage during a pre-mating period of about 10 weeks, a mating period of up to 3 weeks, and, for female animales, during gestation (~ 22 days) and weaning (~ 28 days).
At 1000 mg/kg only for males of F0-generation basophilic tubules were slightly increased by severity and minimal focal tubular dilation/casts were slightly more frequent at 1000 mg/kg. Although basophilic tubules and focal tubular dilation/hyaline casts are common spontaneous findings in male rats of this age these findings were concluded to be adverse, since they correlated with statistically significantly elevated absolute and/or relative kidney weights, evident for F0 and F1 rats at 1000 mg/kg. For F0 females slightly more frequent slight non-adverse tubular change of inner renal cortex were found at 1000 mg/kg and for F1 rats kidney histopathology was inconspicuous. No other test substance related findings were reported. Thus, the LOAEL for general toxicity of the study is 1000 mg/kg and the NOAEL is 200 mg/kg, based on mild effects in male rats only.
The studies were performed with aspartic acid, N,Nā-[methylenebis(2-methyl-4,1-cyclohexanediyl)]bis-, 1,1',4,4'-tetraethyl ester which is a structural analogue to aspartic acid, N,Nā-(methylenedi-4,1-cyclohexanediyl)bis-, 1,1',4,4'-tetraethyl ester. Both substances are diethyl esters of aspartic acid linked to a dicyclohexylmethyldiamine moiety. The difference between these two substances is merely the presence of two methyl groups connected to the cyclohexane rings. This structural analogy was confirmed by the Member State responsible for the notification of both substances under the NONS regulation. The Member State decided that test results obtained for one substance can be transferred to the other substance and that testing of both substances is usually not required. This decision is in accordance with the grouping of substances and read-across approach in Annex XI, 1.5 of the REACH Regulation.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
A subacute (28 days) repeated dose study is available for the read across substance showing no toxicological effects up to the highest dose tested (NOAEL = 1000 mg/kg). A two-generation toxicity study (subchronic) reveals a LOAEL of 1000 mg/kg (NOAEL = 200 mg/kg), due to mild effects on male rats kidney. This value is used for risk assessment.
Justification for classification or non-classification
No classification required according to EU-Directive 67/548/EEC, Annex I
No classification required according to Regulation (EC) No 1272/2008, Annex VI.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.